Recardio is developing novel therapies that modulate and utilize the body’s own repair mechanisms in cardiovascular, oncology, and infectious diseases. Our lead candidate Dutogliptin is intended to enable cardiac regeneration in patients with Acute Myocardial Infarction (AMI) and Advanced Heart Failure (HF).
Recardio is a clinical stage life sciences company headquartered in San Francisco, California.
Our multinational management team and our scientific and clinical advisors are based in the US and in Europe.
Recardio’s global and multicenter Phase 2B study was completed and evaluated the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.
Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking to expand our team.